When is AccurKardia the better choice?

The ECG analysis is cleared Class II software operating on tracings the health system already captures, so the input is standard and the output is a near automated interpretation. It is device agnostic across ECG sources, which matters because signal characteristics vary by manufacturer before any patient variation enters the picture. For an organisation with volumes of unread or slowly read tracings, the constraint is interpretation capacity and that is exactly what this addresses.

When is Eko Health the better choice?

It analyses ECG and heart sound together during a routine physical exam, which surfaces structural findings such as low ejection fraction that a tracing alone will not. A decade of stacked clearances each tied to a stated indication, plus the only randomised trial evidence on this side of the index. The reimbursement position is disclosed, which is the half of the economics that usually decides whether a primary care organisation adopts the workflow at all.

AccurKardia vs Eko Health

Last VerifiedAugust 4, 2026

Verdict

Both find cardiac disease from a signal, and they collect that signal in different places. AccurKardia analyses the electrocardiogram itself, cleared Class II software producing near automated interpretation and deliberately device agnostic across ECG sources, which suits an organisation drowning in tracings that take too long to read. Eko puts detection inside the stethoscope, analysing ECG and heart sound together during a routine exam, which surfaces structural disease such as low ejection fraction that a tracing will not show, with a decade of stacked clearances and randomised evidence behind it. The dividing line is whether you are trying to read what you already collect faster, or to detect something during an exam that is not being looked for at all. Neither publishes performance by sex, age or body habitus, which is the number both should be asked for.

Select AccurKardia if

The ECG analysis is cleared Class II software operating on tracings the health system already captures, so the input is standard and the output is a near automated interpretation.
It is device agnostic across ECG sources, which matters because signal characteristics vary by manufacturer before any patient variation enters the picture.
For an organisation with volumes of unread or slowly read tracings, the constraint is interpretation capacity and that is exactly what this addresses.

Select Eko Health if

It analyses ECG and heart sound together during a routine physical exam, which surfaces structural findings such as low ejection fraction that a tracing alone will not.
A decade of stacked clearances each tied to a stated indication, plus the only randomised trial evidence on this side of the index.
The reimbursement position is disclosed, which is the half of the economics that usually decides whether a primary care organisation adopts the workflow at all.

Attribute Matrix

Side by Side

Axis	A AccurKardia	E Eko Health
AI Centrality
Autonomy and Oversight Model
Model and Technology Transparency
Clinical and Operational Evidence
AI Safety and PHI Stewardship
HIPAA and BAA Posture
Security Certifications and Trust Center
FDA and Regulatory Status
AI Governance and Bias Disclosure
EHR and Interoperability Depth
Deployment Model and Data Residency
Commercial Transparency
Setting and Specialty Coverage

Keep Comparing

Related comparisons

Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.

AccurKardia vs HeartSciences→Digital Diagnostics vs Eko Health→Abstractive Health vs xCures→AgileMD vs Bayesian Health→Aidoc vs Bunkerhill Health→Aidoc vs Qure AI→

Disclosure

Neither vendor publishes subgroup or population performance, and the omission has a specific shape in cardiac signal analysis: heart sound quality varies with body habitus, and ECG morphology varies with sex, age and race, so a sensitivity figure quoted without that breakdown describes the cohort it was measured in rather than your patients. Eko publishes no health privacy or business associate detail and no commercial attestation was located.

Both are detection aids rather than diagnoses, so the clinician remains the decision point, and the useful evaluation question is what proportion of flagged patients complete the confirmatory test rather than what proportion were flagged.